Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
PHA121 is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist. Data from Phase 1 studies in healthy volunteers demonstrate rapid exposure and predictable linear pharmacokinetics, and inhibition of bradykinin-induced hemodynamic changes in a human bradykinin-challenge study. PHVS416, a softgel capsule formulation containing PHA121, is currently in Phase 2 clinical development for the on-demand treatment of HAE.
Pharvaris was founded in October 2015 by executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.
Nov 10, 2022Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022
Oct 07, 2022Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop
Sep 30, 2022Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer
More events are coming soon.